Opportunity
Hawaii eProcurement Portal #B26002727
Statewide Procurement of 12-Panel Drug Test Kits with Fentanyl Detection for Hawaii Paroling Authority
Posted
May 11, 2026
Respond By
June 04, 2026
Identifier
B26002727
NAICS
424210
The Hawaii Paroling Authority (HPA), under the State of Hawaii Department of Corrections and Rehabilitation, is seeking bids for a statewide contract to supply integrated urine-based 12-panel drug test kits with fentanyl detection for use in clinical monitoring and early intervention of supervised individuals. - Government Buyer: - State of Hawaii, Department of Corrections and Rehabilitation, Hawaii Paroling Authority (HPA), Rehabilitation Services - Products/Services Requested: - Integrated urine-based 12-panel drug testing kits (approx. 6,000 kits annually) - Must detect: THC, Buprenorphine, Benzodiazepines, Methadone, Amphetamines, Oxycodone, Opiates, MDMA/Ecstasy, Cocaine, Methamphetamine, Alcohol (EtG), and Fentanyl - Kits must be FDA 510(k)-cleared (where applicable), meet CLIA standards, have a minimum 12-month shelf life, provide rapid and clear results, and include lot number traceability - No separate add-on strips; all analytes must be integrated - Shipments of 100-400 kits per order, delivered as needed - Unique/Notable Requirements: - Vendors must be authorized distributors or manufacturers - Products must comply with all regulatory requirements (FDA, CLIA) - Detailed product specifications and documentation required - Delivery to multiple HPA offices across Oahu, Hawaii Island (Hilo and Kona), Maui, and Kauai - OEMs and Vendors: - No specific OEMs or brands are named; opportunity is open to all qualified manufacturers and authorized distributors meeting the technical and regulatory standards
Description
The Hawaii Paroling Authority (HPA) is soliciting competitive sealed bids to establish a statewide price list contract for the purchase and delivery of integrated urine-based 12-panel drug testing kits with fentanyl detection capabilities. These kits will support clinical monitoring, treatment compliance, early intervention, and relapse detection for supervised individuals across multiple Hawaiian islands. The contract term is from July 1, 2026, through June 30, 2027, with options to extend for up to three additional years. Estimated annual usage is approximately 6,000 kits, with deliveries to offices on Oahu, Hawaii Island, Maui, and Kauai.